Researchers surveyed 1,006 women who were treated for early stage breast cancer and were employed at the time of their diagnosis.
The study, led by Professor Reshma Jagsi from University of Michigan in the US, found that use of chemotherapy, race and differences in employment support - including paid sick leave and flexible working schedules - all had an impact on whether women lost more than a month of work or stopped working entirely after treatment.
The study, published in the journal Cancer, found that women who opted for a bilateral mastectomy with reconstruction had 7.8 times the odds of missing more than a month of work or stopping work altogether, compared to women who opted for a lumpectomy and radiation therapy.
"It really stood out, especially because bilateral mastectomy has not been demonstrated to improve survival, and clearly has a negative impact on employment," said Jagsi.
"But as we have had success reducing over treatment with chemotherapy, we are now seeing a paradoxical increase in what may be over treatment with surgery," said Jagsi.
With the growing use of mastectomy, fuelled by celebrity disclosures and growing patient interest, further research is necessary to monitor whether the short-term employment consequences seen in this study will translate into longer term impacts on these women's employment and well-being, researchers said.
Disclaimer: No Business Standard Journalist was involved in creation of this content